Medicorp’s Licensee for Passive Hyperimmune Therapy AIDS Drug Receives California Conditional Approval for Phase III Clinical Trial: Hemacare Corporation Plans National Clinical Trials of Immupath(TM)

For full access to this item, please log in.

Title: Medicorp’s Licensee for Passive Hyperimmune Therapy AIDS Drug Receives California Conditional Approval for Phase III Clinical Trial: Hemacare Corporation Plans National Clinical Trials of Immupath(TM)
Author: Medicorp, Inc.
Publication: Medicorp, Inc.; 1992-10-01
Rights/Permissions: The University of Michigan Library provides access to these materials for educational and research purposes, with permission from their copyright holder(s). If you decide to use any of these materials, you are responsible for making your own legal assessment and securing any necessary permission.
Subject terms: press releases
Series/Folder Title: Scientific Research > Pediatrics > HIV Hyperimmune Globulin
Item type:: press releases
Link to this Item: https://quod.lib.umich.edu/c/cohenaids/5571095.0281.034
Cite this Item: "Medicorp’s Licensee for Passive Hyperimmune Therapy AIDS Drug Receives California Conditional Approval for Phase III Clinical Trial: Hemacare Corporation Plans National Clinical Trials of Immupath(TM)." In the digital collection Jon Cohen AIDS Research Collection. https://quod.lib.umich.edu/c/cohenaids/5571095.0281.034. University of Michigan Library Digital Collections. Accessed May 11, 2025.

Contents